These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10508030)

  • 1. Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.
    Kenny GE; Young PA; Cartwright FD; Sjöström KE; Huang WM
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2493-6. PubMed ID: 10508030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
    Bébéar CM; Renaudin H; Charron A; Bové JM; Bébéar C; Renaudin J
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2304-11. PubMed ID: 9736554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
    Gushchin AE; Ladygina VG; Govorun VM
    Mol Gen Mikrobiol Virusol; 1999; (4):19-24. PubMed ID: 10621934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
    Dessus-Babus S; Bébéar CM; Charron A; Bébéar C; de Barbeyrac B
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2474-81. PubMed ID: 9756744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of regions determining resistence to fluoroquinolones in genes gyrA and parC in clinical isolates of Mycoplasma hominis].
    Gushchin AE; Ladygina VG; Govorun VM; Taraskina AM; Savicheva AM
    Mol Gen Mikrobiol Virusol; 2000; (4):33-5. PubMed ID: 11186458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.
    Bebear CM; Renaudin J; Charron A; Renaudin H; de Barbeyrac B; Schaeverbeke T; Bebear C
    Antimicrob Agents Chemother; 1999 Apr; 43(4):954-6. PubMed ID: 10103208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones.
    Bebear CM; Bové JM; Bebear C; Renaudin J
    Antimicrob Agents Chemother; 1997 Feb; 41(2):269-73. PubMed ID: 9021178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
    Kumagai Y; Kato JI; Hoshino K; Akasaka T; Sato K; Ikeda H
    Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Formation of M. hominis and A. laidlawii resistance to fluoroquinolones].
    Govorun VM; Gushchin AE; Ladygina VG; Abramycheva NIu; Topol' IuIu
    Mol Gen Mikrobiol Virusol; 1998; (3):16-9. PubMed ID: 9819821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.